/
CTNM
$15.00+$0.81 (+5.71%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$530.5M
37M shares
52-week range
$3.72 – $16.33
89% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.35%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-0.40
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $50.0M | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $258.0K | $0 |
| Gross profit | $0 | $0 | $50.0M | −$258.0K | $0 |
| Gross margin | — | — | 100.0% | — | — |
| R&D | $22.4M | $16.9M | $27.6M | $38.2M | $51.5M |
| Operating income | −$28.6M | −$22.7M | −$16.1M | −$50.9M | −$68.1M |
| EBITDA | −$28.3M | −$23.5M | $23.6M | −$42.0M | −$59.7M |
| Net income | −$29.0M | −$24.3M | $22.7M | −$42.3M | −$60.0M |
| Net margin | — | — | 45.4% | — | — |
| EPS (diluted) | -1.15 | -0.97 | 0.13 | -1.63 | -2.17 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $7M | $-1.65 | $-1.76–$-1.49 | 5 |
| 2027 | $2M | $-1.81 | $-2.05–$-1.44 | 5 |
| 2028 | $3M | $-1.91 | $-1.91–$-1.91 | 2 |
| 2029 | $23M | $-2.01 | $-2.01–$-2.01 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.40
Price
$15.00
Implied downside
-84%
Peer comparison
Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
www.contineum-tx.com- Employees
- 51
- IPO / List date
- Apr 5, 2024
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds CTNM.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 69,400 | $906.4K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CTNM yet.
